Kelong Han

1.5k total citations
41 papers, 928 citations indexed

About

Kelong Han is a scholar working on Infectious Diseases, Epidemiology and Hepatology. According to data from OpenAlex, Kelong Han has authored 41 papers receiving a total of 928 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 17 papers in Epidemiology and 12 papers in Hepatology. Recurrent topics in Kelong Han's work include HIV/AIDS drug development and treatment (13 papers), Hepatitis C virus research (10 papers) and HIV Research and Treatment (9 papers). Kelong Han is often cited by papers focused on HIV/AIDS drug development and treatment (13 papers), Hepatitis C virus research (10 papers) and HIV Research and Treatment (9 papers). Kelong Han collaborates with scholars based in United States, United Kingdom and Belgium. Kelong Han's co-authors include Raman Venkataramanan, René Bruno, Blair Capitano, Laurent Claret, Amita Joshi, David E. Allison, Robert R. Bies, James Jin, Min Ren and Manish Gupta and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Kelong Han

40 papers receiving 905 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kelong Han United States 18 250 248 220 144 128 41 928
Masatoshi Wakui Japan 19 160 0.6× 229 0.9× 168 0.8× 404 2.8× 110 0.9× 72 1.6k
Steven Lacy United States 19 134 0.5× 346 1.4× 419 1.9× 333 2.3× 114 0.9× 29 1.2k
Andrew Reid United Kingdom 15 469 1.9× 199 0.8× 181 0.8× 289 2.0× 99 0.8× 34 1.1k
Akiko Hori Japan 21 228 0.9× 288 1.2× 294 1.3× 284 2.0× 38 0.3× 61 1.3k
Charles E. Hill United States 19 216 0.9× 175 0.7× 404 1.8× 294 2.0× 90 0.7× 80 1.5k
Anoma Nellore United States 15 239 1.0× 205 0.8× 289 1.3× 273 1.9× 57 0.4× 38 1.2k
Christina Rieger Germany 18 395 1.6× 425 1.7× 357 1.6× 107 0.7× 38 0.3× 44 1.2k
Antonio Russo Italy 17 136 0.5× 228 0.9× 205 0.9× 168 1.2× 113 0.9× 64 1.0k
D. Sayer Australia 18 468 1.9× 309 1.2× 105 0.5× 245 1.7× 36 0.3× 52 2.6k
Adan Rios United States 15 130 0.5× 136 0.5× 465 2.1× 235 1.6× 57 0.4× 67 1.2k

Countries citing papers authored by Kelong Han

Since Specialization
Citations

This map shows the geographic impact of Kelong Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kelong Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kelong Han more than expected).

Fields of papers citing papers by Kelong Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kelong Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kelong Han. The network helps show where Kelong Han may publish in the future.

Co-authorship network of co-authors of Kelong Han

This figure shows the co-authorship network connecting the top 25 collaborators of Kelong Han. A scholar is included among the top collaborators of Kelong Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kelong Han. Kelong Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Han, Kelong, et al.. (2025). Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs. Clinical Pharmacology in Drug Development. 14(4). 281–291. 2 indexed citations
2.
D’Amico, Ronald, Kelong Han, Sherene Min, et al.. (2025). Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1. AIDS. 39(15). 2182–2190. 1 indexed citations
3.
4.
Marbury, Thomas, et al.. (2024). A Phase 1, Single‐Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B‐Assured). Clinical Pharmacology in Drug Development. 13(10). 1088–1097. 1 indexed citations
5.
Marzinke, Mark A., Kelong Han, Brett Hanscom, et al.. (2024). Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084. Antimicrobial Agents and Chemotherapy. 68(11). e0099424–e0099424.
6.
Han, Kelong, Parul Patel, Scott McCallister, et al.. (2024). Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrobial Agents and Chemotherapy. 68(6). e0147523–e0147523. 2 indexed citations
7.
Jucker, Beat M., Edward J. Fuchs, Sarah Lee, et al.. (2021). Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers. British Journal of Clinical Pharmacology. 88(4). 1655–1666. 20 indexed citations
8.
Patel, Parul, Susan L. Ford, Herta Crauwels, et al.. (2019). 2495. Pharmacokinetics of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injectables in HIV-infected Individuals through 48 Weeks in the FLAIR and ATLAS Phase 3 Studies. Open Forum Infectious Diseases. 6(Supplement_2). S865–S866. 17 indexed citations
9.
Han, Kelong, Mathilde Marchand, Angelica Quartino, et al.. (2016). Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemotherapy and Pharmacology. 78(2). 341–351. 55 indexed citations
10.
Han, Kelong, et al.. (2016). Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation. BMC Cancer. 16(1). 473–473. 7 indexed citations
11.
Han, Kelong, Pascal Chanu, Fredrik Jönsson, et al.. (2016). Exposure–Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer. The AAPS Journal. 19(2). 527–533. 12 indexed citations
12.
Han, Kelong, Jin Y. Jin, Mathilde Marchand, et al.. (2015). Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 76(5). 917–924. 22 indexed citations
13.
14.
15.
Han, Kelong, Min Ren, Wolfgang Wick, et al.. (2013). Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro-Oncology. 16(5). 696–706. 106 indexed citations
16.
Han, Kelong, Venkateswaran C. Pillai, & Raman Venkataramanan. (2013). Population Pharmacokinetics of Cyclosporine in Transplant Recipients. The AAPS Journal. 15(4). 901–912. 31 indexed citations
17.
Goyal, Rakesh K., Kelong Han, Donna A. Wall, et al.. (2012). Sirolimus Pharmacokinetics in Early Postmyeloablative Pediatric Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation. 19(4). 569–575. 12 indexed citations
18.
Beigi, Richard H., Kelong Han, Raman Venkataramanan, et al.. (2011). Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. American Journal of Obstetrics and Gynecology. 204(6). S84–S88. 53 indexed citations
19.
Han, Kelong, Robert R. Bies, Heather Johnson, Blair Capitano, & Raman Venkataramanan. (2011). Population Pharmacokinetic Evaluation with External Validation and Bayesian Estimator of Voriconazole in Liver Transplant Recipients. Clinical Pharmacokinetics. 50(3). 201–214. 38 indexed citations
20.
Krown, Susan E., Debasmita Roy, Jeannette Y. Lee, et al.. (2011). Rapamycin With Antiretroviral Therapy in AIDS-Associated Kaposi Sarcoma. JAIDS Journal of Acquired Immune Deficiency Syndromes. 59(5). 447–454. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masatoshi Wakui Breakdown of academic impact, for papers by Steven Lacy Breakdown of academic impact, for papers by Andrew Reid Breakdown of academic impact, for papers by Akiko Hori Breakdown of academic impact, for papers by Charles E. Hill Breakdown of academic impact, for papers by Anoma Nellore Breakdown of academic impact, for papers by Christina Rieger Breakdown of academic impact, for papers by Antonio Russo Breakdown of academic impact, for papers by D. Sayer Breakdown of academic impact, for papers by Adan Rios
Rankless by CCL
2026